Back to top
more

Align Technology (ALGN)

(Delayed Data from NSDQ)

$136.90 USD

136.90
2,127,825

-2.75 (-1.97%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $136.96 +0.06 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 246)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Align Technology, based in California, manufactures and markets a system of clear aligner therapy, intra-oral scanners and CAD/CAM (computer-aided design and computer-aided manufacturing) digital services used in dentistry, orthodontics, and dental records storage. The clear aligner system corrects malocclusion using nearly invisible and removable appliances that gently move the tooth to a desired final position.

Zacks Equity Research

Allscripts (MDRX) Declines 1.9% Despite Q3 Earnings Beat

by Zacks Equity Research

Allscripts (MDRX) witnessed decline in core Client Services and Software delivery unit revenues during the third quarter.

Zacks Equity Research

Align Technology (ALGN) Upgraded to Strong Buy: Here's What You Should Know

by Zacks Equity Research

Align Technology (ALGN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Amedisys (AMED) Beats Q3 Earnings Estimates, Ups 2020 View

by Zacks Equity Research

An impressive Q3 performance by Amedisys' (AMED) Home health and hospice amid the pandemic-led business disruptions buoys optimism.

Zacks Equity Research

Integer Holdings (ITGR) Q3 Earnings Beat Estimates, Down Y/Y

by Zacks Equity Research

Integer Holdings' (ITGR) third-quarter results reflect weak segmental performance.

Zacks Equity Research

Bio-Rad (BIO) Q3 Earnings Surpass Estimates, Margins Rise

by Zacks Equity Research

Bio-Rad's (BIO) third-quarter 2020 results reflect strong performance by the Life Science segment, boosted by coronavirus-led increased testing demand.

Zacks Equity Research

Stryker (SYK) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Stryker's (SYK) third-quarter earnings reflect strong segmental performance.

Zacks Equity Research

Merit Medical (MMSI) Rallies 4.8% Post Q3 Earnings Beat

by Zacks Equity Research

Merit Medical (MMSI) reported growth in revenues at Cardiovascular segment in the third quarter.

Zacks Equity Research

DaVita (DVA) Earnings Beat Estimates in Q3, Revenues Miss

by Zacks Equity Research

DaVita (DVA) saw strength in dialysis services in the United States in the third quarter.

Zacks Equity Research

Omnicell (OMCL) Q3 Earnings Top, Pre-COVID-19 View Reinstated

by Zacks Equity Research

Omnicell's (OMCL) Service and other revenues improve in Q3 despite the pandemic-led business challenges.

Zacks Equity Research

Is Align Technology (ALGN) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (ALGN) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

Integra (IART) Q3 Earnings Surpass Estimates, Margins Up

by Zacks Equity Research

Integra's (IART) third-quarter 2020 results reflect mixed segmental performance with strong recovery trends due to coronavirus-led business disruptions.

Zacks Equity Research

Globus Medical (GMED) Q3 Earnings Beat, U.S. Business Strong

by Zacks Equity Research

Globus Medical's (GMED) spinal implant business performance varies by region in Q3.

Zacks Equity Research

Baxter (BAX) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Baxter's (BAX) third-quarter results reflect strong performance across six of its business units.

Zacks Equity Research

IDEXX (IDXX) Earnings Beat Estimates in Q3, Margins Rise

by Zacks Equity Research

IDEXX (IDXX) registered strong contribution from its CAG business in the third quarter despite pandemic-induced challenges.

Zacks Equity Research

ABIOMED (ABMD) Earnings and Revenues Beat Estimates in Q2

by Zacks Equity Research

ABIOMED's (ABMD) international Impella revenues improved in Q2.

Zacks Equity Research

CONMED (CNMD) Earnings and Revenues Surpass Estimates in Q3

by Zacks Equity Research

CONMED's (CNMD) General Surgery unit witnessed revenue growth in Q3

Zacks Equity Research

Cerner (CERN) Q3 Earnings Surpass Estimates, Revenues Miss

by Zacks Equity Research

Cerner's (CERN) third-quarter results benefit from gains in Licensed software, Subscriptions and Managed services units, and expansion in margins.

Zacks Equity Research

PerkinElmer (PKI) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

PerkinElmer's (PKI) third-quarter results benefit from growth in Diagnostics segment. However, forex remains a woe.

Trina Mukherjee headshot

3 Dental Supplies Stocks Set to Shine on the Industry's Upturn

by Trina Mukherjee

Despite the challenges thrown by the COVID-19 pandemic, teledentistry coupled with AI & Robotics should lend support to the Zacks Medical - Dental Supplies industry. CAH, WST and MCK are well positioned to gain from the prospects.

Zacks Equity Research

Earnings Estimates Moving Higher for Align Technology (ALGN): Time to Buy?

by Zacks Equity Research

Align Technology (ALGN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Zacks Equity Research

QIAGEN (QGEN) Q3 Earnings Beat Estimates, FY20 Guidance Up

by Zacks Equity Research

QIAGEN (QGEN) registeres robust revenue growth across geographies and both operating segments in Q3 despite the coronavirus-led economic crisis.

Zacks Equity Research

Boston Scientific (BSX) Q3 Earnings Top, Margins Decline

by Zacks Equity Research

Boston Scientific's (BSX) Q3 earnings and revenues decline year over year but improve sequentially.

Zacks Equity Research

Top Ranked Momentum Stocks to Buy for October 27th

by Zacks Equity Research

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, October 27th

Zacks Equity Research

Align (ALGN) Unveils New Product for Better Treatment Option

by Zacks Equity Research

Align Technology's (ALGN) latest product to aid in improving doctor performance and ensure better treatment planning.

Zacks Equity Research

CAH vs. ALGN: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

CAH vs. ALGN: Which Stock Is the Better Value Option?